Advertisement
Screener

Codexis, Inc. (CDXS) Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount

2.5 / 5 stars · 51/101 Roast Me

Codexis, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount

Codexis, Inc. (CDXS) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-03-11

  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2025-12-31 was $300.00K, a 89.97% decline year-over-year.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-12-31 was $2.99M, a 64.12% decline year-over-year.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-09-30 was $3.90M, a 0.00% change year-over-year.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-12-31 was $8.34M.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $300.00K, a 95.65% decline from fiscal 2024.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $6.90M, a 43.50% decline from fiscal 2023.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $12.21M.
  • Codexis, Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $0.00.
Period endEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month
2025-12-31$300.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
$300.00K
10-K · filed 2026-03-11
2025-09-30$0.00
10-Q · filed 2025-11-06
2024-12-31$2.99M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
$6.89M
derived: sum of 2 quarters · filed 2026-03-11
$6.90M
10-K · filed 2026-03-11
2024-09-30$3.90M
10-Q · filed 2025-11-06
$3.91M
10-Q · filed 2025-11-06
2023-12-31$8.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11
$12.24M
derived: sum of 2 quarters · filed 2026-03-11
$12.21M
10-K · filed 2026-03-11
2023-09-30$3.90M
10-Q · filed 2024-10-31
$3.88M
10-Q · filed 2024-10-31
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$0.00
10-K · filed 2025-02-27
2022-09-30$0.00
10-Q · filed 2023-11-03
2021-12-31$0.00
10-K · filed 2024-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
XCF Global, Inc. (SAFX)United States$0.171B-2.86
AEMETIS, INC (AMTX)United States$0.128B-1.95
Comstock Inc. (LODE)United States$0.195B-5.19
LanzaTech Global, Inc. (LNZA)United States$0.078B0.52
FutureFuel Corp. (FF)United States$0.225B-6.53
Alto Ingredients, Inc. (ALTO)United States$0.289B8.52
TOMI Environmental Solutions, Inc. (TOMZ)United States$0.012B
Gevo, Inc. (GEVO)United States$0.345B-1.72
Westlake Chemical Partners LP (WLKP)United States$0.754B2.35
Green Plains Inc. (GPRE)United States$1.054B8.70